Nurix Therapeutics
NRIX
211 hedge funds and large institutions have $2.84B invested in Nurix Therapeutics in 2026 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 66 increasing their positions, 64 reducing their positions, and 28 closing their positions.
266% more call options, than puts
Call options by funds: $6.23M | Put options by funds: $1.7M
68% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 28
57% more capital invested
Capital invested by funds: $1.81B → $2.84B (+$1.03B)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
8% more funds holding
Funds holding: 196 → 211 (+15)
3% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 64
0.2% more ownership
Funds ownership: 113.19% → 113.4% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$81M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.6M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$26.4M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$23.7M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$62.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$36.5M |
| 3 |
CC
Commodore Capital
New York
|
-$35.3M |
| 4 |
LP
Longaeva Partners
Chicago,
Illinois
|
-$23.1M |
| 5 |
GA
General Atlantic
New York
|
-$18.2M |
NRIX Hedge Fund Activity: Q2 2026 in Review
211 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2026, worth a combined $2.84B — up 57% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new NRIX positions and 28 closed out — a net gain of 19 holders — while 66 added to existing stakes and 64 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $81M. The largest seller was Redmile Group, cutting an estimated $62.3M.
- 211 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2026, up from 196 in Q1 2026.
- Funds reported $2.84B of Nurix Therapeutics stock for Q2 2026, up 57% quarter-over-quarter.
- 47 funds opened new Nurix Therapeutics positions in Q2 2026 and 28 closed out, a net change of +19 holders.
- The largest Nurix Therapeutics buyer in Q2 2026 was Rubric Capital Management (New York), an estimated $81M added.
- The largest Nurix Therapeutics seller in Q2 2026 was Redmile Group, an estimated $62.3M sold.
Based on aggregated 13F filings for Q2 2026.